Drugs / QTX3034
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06227377 | Feb 2024 → Apr 2027 expected | cancer | Quanta Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-03-05 | Quanta Therapeutics | Results Quanta Therapeutics Presents Preclinical Data Establishing that Direct Multi-KRAS Inhibitors Retain Strong Activity Against Resistance Mechanisms Acquired from Treatment with pan-RAS Tri-Complex Inhibitors quantatx.com ↗ |
| 2025-10-24 | Quanta Therapeutics | Results Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors quantatx.com ↗
The QTX3034-cetuximab combination displayed compelling anti-tumor activity, including several responses in patients with colorectal cancer (CRC) and pancreatic adenocarcinoma (PDAC). |
| 2024-01-04 | Quanta Therapeutics | Regulatory Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates quantatx.com ↗
Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates |
| 2023-10-11 | Quanta Therapeutics | Results Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference quantatx.com ↗
The combination of QTX3034 and EGFR (epidermal growth factor receptor) inhibitors, a class of drugs used to treat many commonly occurring cancers, demonstrated potent, synergistic anti-tumor activity in preclinical studies. |
| 2023-04-14 | Quanta Therapeutics | Results Quanta Therapeutics Presents Data from KRAS Inhibitor Pipeline at Annual AACR Meeting in Late-Breaking Research Session quantatx.com ↗
QTX3034, a multi-KRAS inhibitor, and QTX3046, a G12D-selective KRAS inhibitor, demonstrate favorable preclinical profiles, including potent anti-tumor activity with oral bioavailability and brain penetration, supporting the initiation of IND-enabling studies and clinical development for KRAS-driven solid tumor indications. |
All press releases naming this drug 6 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QTX3034 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06227377 ↗ |